We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • WCG Clinical
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Breas Medical Ventilators Correction Issued for Possible Formaldehyde Exposure

Breas Medical Ventilators Correction Issued for Possible Formaldehyde Exposure

August 16, 2024
Devices Regulatory Affairs
Breas Medical has initiated a nationwide correction for 8,186 of its Vivo 45 LS ventilator devices after internal testing identified the potential for short term elevated levels of formaldehyde exposure to users under specific conditions.

To View This Article:

Login

Register
Forgot your password?

Subscribe To FDAnews

Buy This Article Now

Add this article to your cart for $25.00

Upcoming Events

  • 21Oct

    MAGI@home Clinical Research Conference 2024

Featured Products

  • From QSR to QMSR: Meeting FDA’s New Requirements

    From QSR to QMSR: Meeting FDA’s New Requirements

  • FDA Oversight of Laboratory Developed Tests

    FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule

Featured Stories

  • Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says

  • Three Device Areas Added to CDRH’s Device-Advancing TAP Program

  • Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand

  • Draft Guidance Covers Using URRAs in Combo Product Applications

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing